CellSight™ DNA
Use
CellSight™ DNA is a next-generation liquid biopsy that analyzes intact circulating tumor cells (CTCs) to provide comprehensive mutation profiling from a single blood draw. It captures the complete biological complexity of cancer, including resistance mechanisms and mutations that fragment-based approaches may miss. This test is particularly useful when tissue biopsy is not feasible, providing genomic insights necessary for precision therapy in a wide range of solid tumors.
Special Instructions
The process is designed to fit seamlessly into existing clinical workflows. Clinicians need to complete the CellSight™ DNA test requisition form and ensure proper specimen collection and handling as per the provided instructions.
Limitations
The test does not detect genomic alterations outside targeted regions, and cannot reliably distinguish between somatic and germline mutations or alterations related to clonal hematopoiesis of indeterminate potential (CHIP) at certain allele frequencies. It is not validated for hereditary cancer risk, germline mutations, or CHIP-associated alterations. Negative findings do not exclude malignancy.
Methodology
NGS (CGP)
Biomarkers
Microsatellite Instability
SignatureTumor Mutational Burden
Signature
Result Turnaround Time
5-7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
10 ml per tube, 2 tubes
Minimum Volume
Not provided
Container
CellSave tubes
Collection Instructions
Draw two 10 ml tubes, fill to line, gently invert 8-10x to mix; do not shake.
Storage Instructions
Place tubes in a biohazard bag with a liner, add frozen ice pack below, seal at 2-8 °C.
Other tests from different labs that may be relevant